InMed Pharmaceuticals Inc. (INM)
NASDAQ: INM · Real-Time Price · USD
4.290
-0.040 (-0.92%)
Dec 3, 2024, 11:27 AM EST - Market open
InMed Pharmaceuticals Income Statement
Financials in millions USD. Fiscal year is July - June.
Millions USD. Fiscal year is Jul - Jun.
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | 2019 - 2015 |
---|---|---|---|---|---|---|---|
Period Ending | Sep '24 Sep 30, 2024 | Jun '24 Jun 30, 2024 | Jun '23 Jun 30, 2023 | Jun '22 Jun 30, 2022 | Jun '21 Jun 30, 2021 | Jun '20 Jun 30, 2020 | 2019 - 2015 |
Revenue | 4.96 | 4.6 | 4.14 | 1.09 | - | - | Upgrade
|
Revenue Growth (YoY) | 5.17% | 11.18% | 279.61% | - | - | - | Upgrade
|
Cost of Revenue | 3.39 | 3.5 | 2.73 | 0.55 | - | - | Upgrade
|
Gross Profit | 1.57 | 1.1 | 1.4 | 0.54 | - | - | Upgrade
|
Selling, General & Admin | 5.37 | 5.25 | 5.85 | 6.67 | 4.48 | 3.23 | Upgrade
|
Research & Development | 3.24 | 3.77 | 3.73 | 7.28 | 5.34 | 5.81 | Upgrade
|
Operating Expenses | 8.84 | 9.24 | 9.78 | 14.14 | 9.94 | 9.15 | Upgrade
|
Operating Income | -7.26 | -8.13 | -8.38 | -13.59 | -9.94 | -9.15 | Upgrade
|
Interest & Investment Income | 0.45 | 0.53 | 0.49 | 0.1 | 0.02 | 0.13 | Upgrade
|
Currency Exchange Gain (Loss) | 0.01 | -0.06 | -0.05 | -0.12 | -0.16 | 0.08 | Upgrade
|
Other Non Operating Income (Expenses) | - | - | - | - | -0.12 | - | Upgrade
|
EBT Excluding Unusual Items | -6.81 | -7.67 | -7.93 | -13.61 | -10.2 | -8.94 | Upgrade
|
Merger & Restructuring Charges | - | - | - | -0.2 | - | - | Upgrade
|
Impairment of Goodwill | - | - | - | -2.02 | - | - | Upgrade
|
Asset Writedown | - | - | - | -1.45 | - | - | Upgrade
|
Other Unusual Items | - | - | - | -1.31 | - | - | Upgrade
|
Pretax Income | -6.81 | -7.67 | -7.93 | -18.6 | -10.2 | -8.94 | Upgrade
|
Income Tax Expense | 0.01 | 0.01 | 0.01 | - | - | - | Upgrade
|
Net Income | -6.82 | -7.68 | -7.95 | -18.6 | -10.2 | -8.94 | Upgrade
|
Net Income to Common | -6.82 | -7.68 | -7.95 | -18.6 | -10.2 | -8.94 | Upgrade
|
Shares Outstanding (Basic) | 0 | 0 | 0 | 0 | 0 | 0 | Upgrade
|
Shares Outstanding (Diluted) | 0 | 0 | 0 | 0 | 0 | 0 | Upgrade
|
Shares Change (YoY) | 222.76% | 211.26% | 336.59% | 108.64% | 28.72% | 0.83% | Upgrade
|
EPS (Basic) | -13.79 | -20.14 | -64.92 | -663.32 | -759.16 | -856.16 | Upgrade
|
EPS (Diluted) | -13.79 | -20.14 | -64.92 | -663.32 | -759.16 | -856.16 | Upgrade
|
Free Cash Flow | -6.65 | -7 | -7.45 | -15.62 | -9.79 | -7.42 | Upgrade
|
Free Cash Flow Per Share | -13.44 | -18.36 | -60.81 | -557.14 | -728.60 | -710.40 | Upgrade
|
Gross Margin | 31.71% | 23.94% | 33.93% | 49.89% | - | - | Upgrade
|
Operating Margin | -146.44% | -176.92% | -202.60% | -1247.60% | - | - | Upgrade
|
Profit Margin | -137.42% | -166.94% | -192.18% | -1707.32% | - | - | Upgrade
|
Free Cash Flow Margin | -134.01% | -152.14% | -180.02% | -1434.03% | - | - | Upgrade
|
EBITDA | -7.04 | -7.91 | -8.18 | -13.41 | -9.82 | -9.04 | Upgrade
|
EBITDA Margin | -142.02% | -172.15% | -197.71% | - | - | - | Upgrade
|
D&A For EBITDA | 0.22 | 0.22 | 0.2 | 0.19 | 0.12 | 0.11 | Upgrade
|
EBIT | -7.26 | -8.13 | -8.38 | -13.59 | -9.94 | -9.15 | Upgrade
|
EBIT Margin | -146.44% | -176.92% | -202.60% | - | - | - | Upgrade
|
Source: S&P Capital IQ. Standard template. Financial Sources.